Disease Overview：Bronchial Asthma（BA）
Bronchial asthma is a chronic inflammatory airway disorder characterized by reversible bronchoconstriction, airway hyperresponsiveness, and remodeling. Patients experience recurrent episodes of wheezing, dyspnea, chest tightness, and cough—often triggered by allergens, infections, exercise, or environmental irritants. Diagnosis relies on clinical history, spirometry with bronchodilator reversibility testing, fractional exhaled nitric oxide (FeNO), and sometimes methacholine challenge. Management follows a stepwise approach per GINA guidelines: inhaled corticosteroids (ICS) as controller therapy, long-acting beta-agonists (LABA) for moderate disease, biologics (e.g., omalizumab, benralizumab) for severe eosinophilic asthma, and non-pharmacologic strategies including trigger avoidance and pulmonary rehabilitation. Uncontrolled asthma increases risk of exacerbations, hospitalization, and irreversible airflow limitation.
China offers distinct advantages for international patients seeking asthma care. Leading respiratory centers—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—host nationally certified asthma specialty clinics staffed by pulmonologists trained in both conventional and precision medicine approaches. Advanced diagnostics include high-resolution CT, FeNO analyzers, and integrated allergy testing platforms. Over 92% of patients in China’s national asthma control programs achieve well-controlled status within six months, supported by real-world data from multicenter registries. Treatment costs are typically 40–60% lower than in the US or Western Europe, with biologics priced at approximately one-third the US list price—without compromising quality or regulatory oversight (NMPA-approved agents). As a dedicated medical tourism agency, we facilitate seamless access to these resources: verifying hospital accreditation, coordinating specialist consultations, providing itemized, transparent pricing in advance, arranging visas and local logistics, and offering multilingual clinical support throughout diagnosis, treatment, and follow-up.
Bronchial Asthma: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Bronchial Asthma (Respiratory Medicine)
Non-Surgical / Conservative / Medication-Based Management
*Target Criteria:* Persistent mild-to-moderate asthma, controlled or partly controlled per GINA 2023; no severe fixed airflow obstruction or frequent exacerbations requiring ICU admission.
- •Stepwise Pharmacotherapy (3–6 months initial course):
- *ICS/LABA combination (e.g., salmeterol/fluticasone DPI):* ¥260–¥520/month → $37–$74 USD - *Leukotriene receptor antagonist (montelukast):* ¥90–¥180/month → $13–$26 USD - *Short-acting beta-agonist (SABA) rescue (salbutamol MDI):* ¥35–¥65/month → $5–$9 USD
- •Diagnostic & Monitoring Fees (One-time or quarterly):
- Fractional exhaled nitric oxide (FeNO): ¥180 → $26 USD - Total IgE & allergen-specific IgE panel (10 allergens): ¥360 → $51 USD - Sputum eosinophil count: ¥150 → $21 USD
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Severe, uncontrolled asthma despite maximal guideline-based therapy (high-dose ICS/LABA + biologics + oral corticosteroids ≥6 months), documented type 2 inflammation (blood/sputum eosinophils ≥150/μL or FeNO ≥50 ppb), no contraindications (e.g., active infection, significant comorbid COPD).
- •Bronchial Thermoplasty (BT):
- Procedure (3-session protocol, each under general anesthesia): ¥38,000–¥45,000 total → $5,400–$6,400 USD - Post-procedure outpatient follow-up (3 visits × PFTs + symptom assessment): ¥660 → $94 USD
Special / Complex Condition Management
- •Biologic Therapy (anti-IL-5/IL-4 agents):
- *Mepolizumab/benralizumab (anti-IL-5):* ¥1,900–¥3,100/dose (q4w or q8w); annual cost ¥22,800–¥37,200 → $3,240–$5,290 USD
- •Oral Corticosteroid–Dependent Asthma:
Quick Selection Guide
- •Children (<12 years, mild intermittent): SABA PRN + low-dose ICS; total 6-month cost ≈ $120–$220 USD
- •Adults (moderate, budget-constrained): Generic ICS/LABA + FeNO monitoring; annual cost ≈ $650–$950 USD
- •Severe adult (biologic-eligible, stable income): Omalizumab + BT if refractory; first-year cost ≈ $10,200–$12,800 USD
- •Elderly (>70 years, multiple comorbidities): Low-dose ICS + LAMA (e.g., tiotropium), avoid BT; annual cost ≈ $580–$820 USD
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Bronchial Asthma Medical Vacation Packages
Curated transparent all-inclusive packages combining Bronchial Asthma treatment with China top medical destinations:
